Replies to post #2591 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Paxlovid sales for the first quarter came in at $4.1 billion, which far exceeded Wall Street's expectation of $2.7 billion. The result also was a $2.8 billion increase from the same period in 2022. Pfizer chalked up the performance to strong demand in China and to new launches in other international markets.

Lishur, thanks for your post. It brings up two very important issues.

First, that level of Paxlovid sales vividly illustrates how the market seems to have discounted the blockbuster potential for EDP-235. Now if ENTA can just get a partnership for EDP-235 so the phase 3 trials and begin to make this closer to a reality.

Pfizer’s infringement has damaged and will continue to damage Enanta, which is entitled to recover damages adequate to compensate for Pfizer’s infringement in an amount to be determined at trial, and in any event no less than a reasonable royalty for the use made by Pfizer
of Enanta’s invention.

Second, the market seems to be ignoring the potential windfall for ENTA in this patent infringement suit.